Inhibitor which is deactivatable by a reagent produced by a target cell

• US 8,809,504 B2
• Filed: 08/30/2003
• Issued: 08/19/2014
• Est. Priority Date: 09/03/2002
• Status: Active Grant

• Current Assignee: Vytacera Bio, LLC
• Original Assignee: Vit Lauermann
• Inventors: Lauermann, Vit
• Primary Examiner(s): Chandra, Gyan
• Application Number:
  US10/651,584
• Publication Number:
  US 20040259768A1
• Time in Patent Office: 4,007 Days
• Field of Search: None
• US Class Current: 530/387.3
• CPC Class Codes: A61K 2039/505 comprising antibodies
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: A61K 38/2013 IL-2
• CPC Class Codes: A61K 47/65 Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
• CPC Class Codes: C07K 14/4703 Inhibitors; Suppressors
• CPC Class Codes: C07K 14/70575 NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154 NGF C07K14/48, TNF C07K14/525
• CPC Class Codes: C07K 14/70578 NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95 NGF-receptor C07K14/71, TNF-receptor C07K14/7151
• CPC Class Codes: C07K 16/246 IL-2
• CPC Class Codes: C07K 16/40 against enzymes
• CPC Class Codes: C07K 2317/76 Antagonist effect on antigen, e.g. neutralization or inhibition of binding
• CPC Class Codes: Y02A 50/30 Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

The invention relates to molecules inhibiting biologically active compounds and further comprising moieties specifically cleavable by a reagent produced by a target cell. The invention relates to inhibitors that bind, inhibit, suppress, neutralize, or decrease activity of a biologically active agent. Inhibitors comprise at least one moiety that bind, inhibit, suppress, neutralize, or decrease activity of a biologically active agent and at least one moiety that can be cleaved specifically by a reagent produced by target cells. The cleavage deactivates the inhibitor. Following cleavage, the active agent is liberated into the local environment. Administration of the inhibitor alone or together with the active agent suppress the compound'"'"'s activity until it reaches the proximity of a target cell. Targeted specific release enables the agent concentration in specific site to reach levels that have desired therapeutic effects without systemic toxicity.

Claims

1. An inhibitor which is deactivatable by a reagent produced by a target cell comprising:

(a) a first moiety that binds, inhibits, suppresses, neutralizes, or decreases activity of a biologically active agent wherein said first moiety is operably linked to;

(b) a second moiety specifically cleavable by a protease produced by a target cell, wherein said first and second moieties are not attached in nature and wherein specific cleavage of said second moiety causes reduction of binding activity of said inhibitor.

2. The inhibitor of claim 1, wherein said first moiety is selected from the group consisting of a peptide, a cyclic peptide, or a polypeptide.

3. The inhibitor of claim 1, wherein the first moiety is selected from the group consisting of an antibody, or a conjugate of the above.

4. The inhibitor of claim 1, wherein said inhibitor is selected from the group consisting of an antibody inhibitor, or a dimer or multimer of the above.

5. The inhibitor of claim 1, wherein said active agent is selected from the group consisting of an interleukine.

6. The inhibitor of claim 1 wherein at least one said second moiety is operably linked to the first moiety.

7. The inhibitor of claim 1 wherein said first and second moieties are connected by a peptide, or a chemical linker.

8. The inhibitor of claim 1, wherein said second moiety is selected from the group consisting of a peptide, a polypeptide, or a conjugate of the above.

9. The inhibitor of claim 1 wherein said second moiety is a peptide which comprises a sequence cleavable by a protease.

10. The inhibitor of claim 1 wherein the second moiety is selected from the group consisting of HSSKLQ (SEQ ID NO:

17) or a combination thereof.

11. The inhibitor of claim 1 wherein said reagent is selected from the group consisting of a protease.

12. The inhibitor of claim 1 wherein said reagent is selected from the group consisting of a prostate specific antigen.

13. The inhibitor of claim 1 wherein said reagent is produced by activated or proliferating endothelial cells, tumor cells, or leukemia cells.

14. The inhibitor of claim 1 wherein the inhibitor alone or together with an active agent is in a biodegradable, biocompatible polymeric delivery material, in a slow release implant, in a microencapsulated composition, or a conjugate with a biodegradable polymer.

15. The inhibitor of claim 1 which further comprises or associates with a recognition domain that binds to a target structure, an exterior surface of a targeted cell, a cell surface marker, an extracellualr matrix, or components thereof.

16. The inhibitor of claim 15, wherein said recognition domain binds to activated or proliferating endothelial cells, to tumor cells, or to leukemia cells.

17. The inhibitor of claim 15, wherein said recognition domain is selected from the group consisting of an antibody, a monoclonal antibody, a bispecific antibody, an antibody fragment, a single chain antibody, a peptabody, or compositions and variants thereof.